Kanagawa Cancer Center

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. National Cancer Center Hospital East日本2
2. Pfizer (Japan)日本1
3. Osaka International Cancer Institute日本1
4. Kobe University日本1
5. Pfizer (United States)美国1
6. Chugai Pharmaceutical Co., Ltd. (Japan)日本1
7. University of Occupational and Environmental Health Japan日本1
8. The Cancer Institute Hospital日本1

按月发文

逐年被引

最新文献

1. 1
   Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J studyPharmacoepidemiology and Drug Safety202142
2. 2
   Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factorsExpert Opinion on Drug Safety202121
3. 3
   Safety evaluation of durvalumab for the treatment of non-small-cell lung cancerExpert Opinion on Drug Safety20207
4. 4
   Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety ResultsDrug Safety201758

高被引文献

1. 1
   Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety ResultsDrug Safety201758
2. 2
   Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J studyPharmacoepidemiology and Drug Safety202142
3. 3
   Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factorsExpert Opinion on Drug Safety202121
4. 4
   Safety evaluation of durvalumab for the treatment of non-small-cell lung cancerExpert Opinion on Drug Safety20207

主要发表期刊